Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
- PMID: 36045670
- PMCID: PMC9422402
- DOI: 10.3389/fimmu.2022.910595
Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
Abstract
Natural killer (NK) cells belong to the family of innate immune cells with the capacity to recognize and kill tumor cells. Different phenotypes and functional properties of NK cells have been described in tumor patients, which could be shaped by the tumor microenvironment. The discovery of HLA class I-specific inhibitory receptors controlling NK cell activity paved the way to the fundamental concept of modulating immune responses that are regulated by an array of inhibitory receptors, and emphasized the importance to explore the potential of NK cells in cancer therapy. Although a whole range of NK cell-based approaches are currently being developed, there are still major challenges that need to be overcome for improved efficacy of these therapies. These include escape of tumor cells from NK cell recognition due to their expression of inhibitory molecules, immune suppressive signals of NK cells, reduced NK cell infiltration of tumors, an immune suppressive micromilieu and limited in vivo persistence of NK cells. Therefore, this review provides an overview about the NK cell biology, alterations of NK cell activities, changes in tumor cells and the tumor microenvironment contributing to immune escape or immune surveillance by NK cells and their underlying molecular mechanisms as well as the current status and novel aspects of NK cell-based therapeutic strategies including their genetic engineering and their combination with conventional treatment options to overcome tumor-mediated evasion strategies and improve therapy efficacy.
Keywords: HLA; NK cells; immune escape; immunotherapy; tumor.
Copyright © 2022 Seliger and Koehl.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.J Leukoc Biol. 2021 Jun;109(6):1071-1088. doi: 10.1002/JLB.5MR0920-198RR. Epub 2020 Sep 29. J Leukoc Biol. 2021. PMID: 32991746 Review.
-
NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.Transplant Cell Ther. 2021 Jan;27(1):21-35. doi: 10.1016/j.bbmt.2020.09.030. Epub 2020 Sep 29. Transplant Cell Ther. 2021. PMID: 33007496 Free PMC article. Review.
-
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?Front Immunol. 2020 Feb 21;11:275. doi: 10.3389/fimmu.2020.00275. eCollection 2020. Front Immunol. 2020. PMID: 32153582 Free PMC article. Review.
-
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.Front Immunol. 2019 Aug 9;10:1782. doi: 10.3389/fimmu.2019.01782. eCollection 2019. Front Immunol. 2019. PMID: 31456796 Free PMC article. Review.
-
Natural killer cells in cancer biology and therapy.Mol Cancer. 2020 Aug 6;19(1):120. doi: 10.1186/s12943-020-01238-x. Mol Cancer. 2020. PMID: 32762681 Free PMC article. Review.
Cited by
-
CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.Int J Mol Sci. 2023 Nov 8;24(22):16065. doi: 10.3390/ijms242216065. Int J Mol Sci. 2023. PMID: 38003255 Free PMC article.
-
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.Biomark Res. 2024 Jul 17;12(1):66. doi: 10.1186/s40364-024-00610-z. Biomark Res. 2024. PMID: 39020411 Free PMC article. Review.
-
Immune Cell Migration to Cancer.Cells. 2024 May 16;13(10):844. doi: 10.3390/cells13100844. Cells. 2024. PMID: 38786066 Free PMC article. Review.
-
Killer instincts: natural killer cells as multifactorial cancer immunotherapy.Front Immunol. 2023 Nov 28;14:1269614. doi: 10.3389/fimmu.2023.1269614. eCollection 2023. Front Immunol. 2023. PMID: 38090565 Free PMC article. Review.
-
The Immunoregulatory Effect of Aconite Treatment on H22 Tumor-Bearing Mice via Modulating Adaptive Immunity and Natural Killer-Related Immunity.Evid Based Complement Alternat Med. 2023 Jan 30;2023:1481114. doi: 10.1155/2023/1481114. eCollection 2023. Evid Based Complement Alternat Med. 2023. PMID: 36756040 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials